Extimia (empegfilgrastim biosimilar) / Biocad 
Welcome,         Profile    Billing    Logout  
 10 Diseases   2 Trials   2 Trials   10 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Extimia (empegfilgrastim biosimilar) / Biocad
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
DEFENDOR, NCT04811443: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

Recruiting
N/A
500
RoW
Empegfilgrastim
Biocad
Patients With Solid Tumours Who Receive Myelosupressive Therapy
06/22
06/22

Download Options